http://orcid.org/0000-0001-5594-0823
References
- Semenas J, Dizeyi N, Persson JL. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Des Devel Ther. 2013;277:875–881.
- Estimation of the variation of exposure due to a drug-drug interaction - DDI-Predictor Academic version [Internet]. [cited 2018 Dec 27]. Available from: https://www.ddi-predictor.org/predictor/ddi
- Parrett JL, Reaves AB, Self TH, et al. Enzalutamide-warfarin interaction necessitating warfarin dosage adjustment: A case report of successful clinical management. J Clin Pharm Ther. 2018;43:276–279.
- Deguigne M, Brunet M, Abbara C, et al. Enzalutamide and analytical interferences in digoxin assays. Clin Toxicol. 2018;56:1150–1154.
- Sellers LE, Savas AN, Prentice M, et al. Prevalence of poly-pharmacy in the prostate cancer clinic and patient interest in a Medicine Review Service. J Oncol Pharm Pract. 2017;23:1–21.
- Veccia A, Maines F, Kinspergher S, et al. Cardiovascular toxicities of systemic treatments of prostate cancer. Nat Rev Urol. 2017;14:230.
- Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54:1057–1069.